This descriptive study examined the use of injections for chronic pain over a ten-year time period and found a threefold increase in the number of injections for chronic pain performed annually and associated costs, rising from 1M blocks ($50M) in 2010 to 3.1M blocks ($157M) in 2019.
This study evaluated the impact of policy changes and drug shortages on the use of acamprosate and naltrexone, evidence-based pharmacotherapies for alcohol use disorder (AUD) in Ontario, Canada.
This report is the first annual update of estimated pharmaceutical drug purchases in Canada for 2022–2023 and found that total drug purchases for 2021 were approximately $35.4 billion, 8.3% higher than in 2020, with forecasts of projected total annual drug purchases nearing $40 billion by 2023.
Contributions of stimulants and varying modes of drug use to opioid toxicity deaths across public health units in Ontario, Canada
This report examines the involvement of stimulants overall, and specifically non-pharmaceutical stimulants (i.e., cocaine and methamphetamines), as well as modes of drug use (e.g. inhalation/smoking vs. injection) in accidental opioid toxicity deaths occurring in Ontario between January 2018 and June 2021.